Sou Hu Cai Jing·2026-01-06 00:25Core Viewpoint - Spring Medical (688236) has shown significant growth in revenue and net profit, indicating strong performance in the orthopedic medical device sector [2]. Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 756 million yuan, an increase of 48.75% year-on-year [2]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [2]. - The net profit after deducting non-recurring items was 181 million yuan, reflecting a 311.07% increase year-on-year [2]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable increase of 109.51% year-on-year [2]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, up 531.12% year-on-year [2]. - The quarterly net profit after deducting non-recurring items was 74.52 million yuan, an increase of 439.4% year-on-year [2]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [2]. - The gross profit margin is reported at 67.27% [2]. Market Activity - As of January 5, 2026, the stock closed at 24.91 yuan, with an increase of 8.87% [1]. - The turnover rate was 1.27%, with a trading volume of 36,600 hands and a transaction amount of 88.41 million yuan [1]. - On January 5, the net outflow of main funds was 3.2551 million yuan, accounting for 3.68% of the total transaction amount [1]. - Retail investors saw a net inflow of 3.7834 million yuan, representing 4.28% of the total transaction amount [1]. Institutional Ratings - In the last 90 days, 8 institutions have given buy ratings for the stock, with an average target price of 31.7 yuan [3].